Swiss pharmaceutical giant Novartis (NYSE: NVS) has this week unveiled six-year efficacy data for its anti-CD20 drug Kesimpta (ofatumumab) in the treatment of recently diagnosed relapsing multiple sclerosis (MS) in treatment-naive patients. The data shows that first-line continuous Kesimpta treatment, as compared to a teriflunomide regimen switched to Kesimpta, resulted in a significant reduction of relapses by 44%. Furthermore, it significantly reduced Gd+ T1 and neT2 lesions by 96.4% and 82.7%, respectively, as well as 3- and 6-month confirmed disability worsening (CDW) events by 24.5% and 21.6%, respectively.
The extension study also demonstrated that Kesimpta was well-tolerated with no unexpected safety signals over the six-year period. Kesimpta has already received global approval for the treatment of relapsing forms of MS, offering a valuable treatment option for patients. – Flcube.com
